Today, Austria enrolled the fourth patient and so went ahead in recruiting.

Altogether, there are worldwide 7 patients randomized in the internationale Phase-III-trial, 3 in the USA and 4 in Austria.

Thanks to the site from ABCSG’s president Michael Gnant, MD for these pleasing news – he has now enrolled 3 patients in ABCSG 42/PALLAS. The first patient out of the USA was randomized in October from the Breastcenter Carinthia and Viktor Wette, MD.

The adjuvant study ABCSG 42/PALLAS evaluates the CDK 4/6-inhibitor Palbociclib with endocrine standard therapy versus endocrine standard therapy alone for male and female breastcancer patients with ER+/HER2-negative carcinoma.